DURECT Corporation (DC8A.F)
| Previous close | 0.8000 |
| Open | 0.8700 |
| Bid | 0.8500 x N/A |
| Ask | 0.9100 x N/A |
| Day's range | 0.8700 - 0.8700 |
| 52-week range | 0.4080 - 6.4000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 30.599M |
| Beta (5Y monthly) | 0.88 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1200 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireDURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis
DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced acceptance of a late-breaking oral presentation at the European Association for the Study of the Liver (EASL) Congress 2024 to take place June 5-8, 2024 in Milan, Italy. The presentation will discuss data from the Company's Phase 2b AHFIRM trial, whi
Insider MonkeyDURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript
DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript March 27, 2024 DURECT Corporation beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.36. DRRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to the DURECT Corporation Full […]
ZacksDurect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
DURECT (DRRX) delivered earnings and revenue surprises of 25% and 1.19%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
